Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-A1811 + everolimus
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
SHR-A1811 + everolimus is a combination therapy being investigated for the treatment of refractory triple-negative breast cancer (TNBC). SHR-A1811 is a next-generation antibody-drug conjugate (ADC) targeting Human Epidermal Growth Factor Receptor 2 (HER2), developed by Jiangsu Hengrui Pharmaceuticals. It consists of a humanized anti-HER2 monoclonal antibody conjugated to a potent topoisomerase I inhibitor payload (SHR152852) via a cleavable linker. Everolimus is an orally active inhibitor of the mechanistic target of rapamycin (mTOR), which plays a key role in cell growth, proliferation, and survival. The combination is being evaluated in a Phase II platform study led by Fudan University (NCT05834140) to explore precision therapy based on molecular subtyping in patients with refractory TNBC, specifically targeting those with HER2-low or HER2-positive expression and potential mTOR pathway activation.
- Brand names
- AfinitorZortressCerticanVotubia
- Other names
- SHR-A1811 plus everolimusSHR-A-1811 plus everolimusSHR-A 1811 plus everolimus
02
Targets
mTOR (Mammalian target of rapamycin kinase)TOP1 (DNA Topoisomerase I)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on SHR-A1811 + everolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-A1811 + everolimus.